CoChat

Cyanidin‐3‐O‐glucoside improves non‐alcoholic fatty liver disease by promoting PINK1‐mediated mitophagy in mice

Open access
Li, Xinwei, Shi, Zhen, Zhu, Yiwei, Shen, Taiyu, Wang, Heyuan, Shui, Guanghou, Loor, Juan J., Fang, Zhiyuan, Chen, Meng, Wang, Xinghui, Peng, Zhicheng, Song, Yuxiang, Wang, Zhe, Du, Xiliang, Liu, Guowen · 2020 · British Journal of Pharmacology
Cited by 143

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

Background and Purpose: Identifying safe and effective compounds that target to mitophagy to eliminate impaired mitochondria may be an attractive therapeutic strategy for non‐alcoholic fatty liver disease. Here, we investigated the effects of cyanidin‐3‐O‐glucoside (C3G) on non‐alcoholic fatty liver disease (NAFLD) and the underlying mechanism. Experimental Approach: Non‐alcoholic fatty liver disease was induced by a high‐fat diet for 16 weeks. C3G was administered during the last 4 weeks. In vivo, recombinant adenoviruses and AAV8 were used for overexpression and knockdown of PTEN‐induced kinase 1 (PINK1), respectively. AML‐12 and HepG2 cells were used for the mechanism study. Key Results: C3G administration suppressed hepatic oxidative stress, NLR family pyrin domain containing 3 (NLRP3) inflammasome activation and steatosis and improved systemic glucose metabolism in mice with NAFLD. These effects of C3G were also observed in palmitic acid‐treated AML‐12 cells and hepatocytes from NAFLD patients. Mechanistic investigations revealed that C3G increased PINK1/Parkin expression and mitochondrial localization and promoted PINK1‐mediated mitophagy to clear damaged mitochondria. Knockdown of hepatic PINK1 abolished the mitophagy‐inducing effect of C3G, which blunted the beneficial effects of C3G on oxidative stress, NLRP3 inflammasome activation, hepatic steatosis and glucose metabolism. Conclusion and Implications: These results demonstrate that PINK1‐mediated mitophagy plays an essential role in the ability of C3G to alleviate NAFLD and suggest that C3G may be a potential drug candidate for NAFLD treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bph.15083

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 19 references

Cited by

See all 143

Metadata

Authors
Li, X., Shi, Z., Zhu, Y., Shen, T., Wang, H., Shui, G., Loor, J. J., Fang, Z., Chen, M., Wang, X., Peng, Z., Song, Y., Wang, Z., Du, X., & Liu, G.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2020-06-14
Volume
177
Issue
15
Pages
3591-3607
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W3017989357
Cited by
143
References
19
FWCI
9.98
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cyanidin‐3‐O‐glucoside improves non‐alcoholic fatty liver disease by promoting PINK1‐mediated mitophagy in mice. https://app.cochat.ai/papers/10.1111/bph.15083
The paper
Li, X., Shi, Z., Zhu, Y., Shen, T., Wang, H., Shui, G., Loor, J. J., Fang, Z., Chen, M., Wang, X., Peng, Z., Song, Y., Wang, Z., Du, X., & Liu, G. (2020). Cyanidin‐3‐O‐glucoside improves non‐alcoholic fatty liver disease by promoting PINK1‐mediated mitophagy in mice. British Journal of Pharmacology. https://doi.org/10.1111/bph.15083

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.